German Spondyloarthritis Inception Cohort

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

The German Spondyloarthritis Inception cohort (GESPIC) was started 2000 as a prospective, longitudinal, multicentre, nationwide study in Germany on patients with early SpA including ankylosing spondylitis (AS, also known as radiographic axial spondyloarthritis) and non-radiographic axial SpA. The objectives of GESPIC are to learn about the course of SpA during the very early stage of the disease, to appropriately assess the outcome including radiographic progression of patients after several years of follow-up, to identify outcome predictors, to assess quality of life, function, and costs (direct and indirect costs). GESPIC has been recently expanded to recruit patients with other forms of SpA / conditions associated with SpA: acute anterior uveitis, Crohn's disease as well as with psoriasis / axial psoriatic arthritis.

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:

• Patients with definite diagnosis of axial spondyloarthritis or juvenile spondyloarthritis.

• Patients with definite diagnosis of Crohn's disease.

• Patients with definite diagnosis of acute anterior uveitis.

• Patients with definite diagnosis of psoriatic arthritis with axial involvement.

Locations
Other Locations
Germany
Charité - Universitätsmedizin Berlin
RECRUITING
Berlin
Contact Information
Primary
Denis Poddubnyy, Prof. Dr.
denis.poddubnyy@charite.de
+4930450514582
Time Frame
Start Date: 2000-07
Estimated Completion Date: 2030-07
Participants
Target number of participants: 1000
Treatments
Ankylosing spondylitis
Ankylosing spondylitis according to the modified New York criteria or with the clinical diagnosis of AS/r-axSpA fulfilling the ASAS Classification Criteria AND the mNY criteria plus having the indiaction for starting a bDMARD therapy according to the treating rheumatologist
Non-radiographic axial spondyloarthritis
Patients with clinical characteristics of axial SpA but not fulfilling the modified New York criteria for which radiographic sacroiliitis is essential or with the clinical diagnosis of nr-axSpA fulfilling the ASAS Classification Criteria not fulfilling the mNY criteria and the indiaction for starting a bDMARD therapy according to the treating rheumatologist
Juvenile spondyloarthritis
Patients with juvenile spondyloarthritis (juvenile ankylosing spondylitis, juvenile non-AS-spondyloarthritis).
Crohn's disease
Patients with Crohn's disease
Acute anterior uveitis
Patients with acute anterior uveitis
Axial psoriatic arthritis
Patients with the clinical diagnosis of psoriatic arthritis with axial involvement (sacroiliac joints and/or spine) (axPsA)
Sponsors
Collaborators: Wyeth is now a wholly owned subsidiary of Pfizer, Schering-Plough, Amgen, Berlin Institute of Health, AbbVie, UCB Pharma, German Federal Ministry of Education and Research, Novartis, Centocor, Inc.
Leads: Charite University, Berlin, Germany

This content was sourced from clinicaltrials.gov

Similar Clinical Trials

We couldn't find any related articles check for more on the main search page.